Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 3:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 165 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Uterine Leiomyoma Clear all
Terminated Phase 3 Interventional Results available

Safety and Efficacy of Proellex in Pre-menopausal Anemic Women With Symptomatic Uterine Fibroids

NCT00702702
View directory record Official record
Conditions
Uterine Fibroids, Anemia
Interventions
Proellex 25 mg, Proellex 50 mg, Placebo
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
30
States / cities
Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2014 · Synced Oct 9, 2026, 3:58 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study Comparing Conventional vs. Robotic-assisted Laparoscopic Hysterectomy

NCT00485355
View directory record Official record
Conditions
Uterine Fibroids, Menorrhagia, Endometriosis
Interventions
conventional laparoscopic hysterectomy, robotic assisted laparoscopic hysterectomy
Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 19, 2014 · Synced Oct 9, 2026, 3:58 PM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Effect of Addition of Steroids on Duration of Analgesia

NCT04126824
View directory record Official record
Conditions
Uterine Fibroids, Adenomyosis
Interventions
Triamcinolone, Bupivacaine, Iohexol contrast
Drug · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
30 Years to 60 Years · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
2
States / cities
Westwood, Los Angeles, California • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 9, 2026, 3:58 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Study of Conventional Laparoscopic Hysterectomy Versus Robot-Assisted Laparoscopic Hysterectomy at a Teaching Institution

NCT01581905
View directory record Official record
Conditions
Menorrhagia, Dysfunctional Uterine Bleeding, Leiomyoma, Pelvic Pain, Endometriosis
Interventions
Conventional Laparoscopic Hysterectomy (LH), Robot Assisted Hysterectomy
Procedure
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 20, 2017 · Synced Oct 9, 2026, 3:58 PM EDT
Completed Phase 4 Interventional Results available

Pilot of Letrozole for Uterine Myomas

NCT02470741
View directory record Official record
Conditions
Leiomyoma, Uterine Fibroids
Interventions
Letrozole, Placebo
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 15, 2019 · Synced Oct 9, 2026, 3:58 PM EDT
Active, not recruiting No phase listed Observational

Ascertaining Longterm Outcomes of Fibroid Treatments

NCT06430320
View directory record Official record
Conditions
Uterine Fibroid
Interventions
NA- no intervention
Other
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older · Female only
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
4
States / cities
San Francisco, California • Detroit, Michigan • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 9, 2026, 3:58 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Uterine Leiomyoma Treatment With Radiofrequency Ablation

NCT01840124
View directory record Official record
Conditions
Uterine Fibroids
Interventions
Radiofrequency ablation of fibroids
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years and older · Female only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2020
U.S. locations
5
States / cities
Davis, California • Irvine, California • La Jolla, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2021 · Synced Oct 9, 2026, 3:58 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women (Replicate Study)

NCT02691494
View directory record Official record
Conditions
Uterine Fibroids, Heavy Menstrual Bleeding
Interventions
Elagolix, Placebo for Estradiol/Norethindrone Acetate, Estradiol/Norethindrone Acetate, Placebo for Elagolix
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 51 Years · Female only
Enrollment
378 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
103
States / cities
Birmingham, Alabama • Dothan, Alabama • Fairhope, Alabama + 89 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Oct 9, 2026, 3:58 PM EDT
Completed Phase 4 Interventional Results available

Deep Versus Moderate Neuromuscular Blockade During Laparoscopic Surgery

NCT02812186
View directory record Official record
Conditions
Cholecystitis, Endometriosis, Bowel Obstruction, Fibroids, Prostate Cancer, Chronic Kidney Disease, Uterine Prolapse
Interventions
Deep to Moderate NMB, Moderate to Deep NMB, Rocuronium
Procedure · Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Apr 8, 2020 · Synced Oct 9, 2026, 3:58 PM EDT
Terminated Phase 2 Interventional Results available

An Extension Study of 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids

NCT02811159
View directory record Official record
Conditions
Uterine Fibroids
Interventions
Telapristone acetate
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 47 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
8
States / cities
Fort Lauderdale, Florida • Atlanta, Georgia • Sandy Springs, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2019 · Synced Oct 9, 2026, 3:58 PM EDT
Enrolling by invitation Not applicable Interventional

Impact of Educational Videos on Pre-operative Anxiety

NCT07740759
View directory record Official record
Conditions
Endometriosis, Fibroids, Adenomyosis, Pelvic Pain, Abnormal Uterine Bleeding, Adnexal Mass, Minimally Invasive Gynecologic Surgery, Hysterectomy, Myomectomy, Ovarian Cystectomy, Adnexal Surgery
Interventions
educational video
Other
Lead sponsor
UConn Health
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 9, 2026, 3:58 PM EDT
Withdrawn No phase listed Observational

A Study to Evaluate Awareness and Knowledge of the Fibristal Additional Risk Minimization Measures Among Patients in Canada

NCT04567095
View directory record Official record
Conditions
Uterine Fibroids
Interventions
Not listed
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 23, 2020 · Synced Oct 9, 2026, 3:58 PM EDT
Terminated Phase 2 Interventional Results available

Pharmacokinetics, Safety and Efficacy Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids

NCT00683917
View directory record Official record
Conditions
Uterine Fibroids
Interventions
Proellex 25 mg, Proellex 50 mg, Lupron Depot
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
3
States / cities
Sarasota, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2014 · Synced Oct 9, 2026, 3:58 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of Safety, Pharmacokinetics, and Efficacy of Proellex Administered Vaginally in Women With Uterine Fibroids

NCT01451424
View directory record Official record
Conditions
Uterine Fibroids
Interventions
Proellex
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 47 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Miami Gardens, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 29, 2014 · Synced Oct 9, 2026, 3:58 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids

NCT03070951
View directory record Official record
Conditions
Uterine Fibroids, Heavy Menstrual Bleeding
Interventions
OBE2109, Placebo to match OBE2109, Placebo to match Add-back, Add-back
Drug
Lead sponsor
ObsEva SA
Industry
Eligibility
18 Years and older · Female only
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
23
States / cities
Chino, California • Huntington Park, California • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2021 · Synced Oct 9, 2026, 3:58 PM EDT
Completed Not applicable Interventional Results available

Safety Study of ExAblate for the Treatment of Uterine Fibroids

NCT01142791
View directory record Official record
Conditions
Uterine Fibroids
Interventions
ExAblate
Device
Lead sponsor
InSightec
Industry
Eligibility
18 Years and older · Female only
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
8
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Oct 9, 2026, 3:58 PM EDT
Not listed No phase listed Observational

Tissue Bank of Biological Specimens From Patients With Gynecologic Disease

NCT00299481
View directory record Official record
Conditions
Endometrial Neoplasms, Uterine Cervical Neoplasms, Ovarian Neoplasms, Leiomyoma
Interventions
Not listed
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years and older · Female only
Enrollment
7,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Detroit, Michigan • Durham, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2008 · Synced Oct 9, 2026, 3:58 PM EDT
Recruiting No phase listed Observational

Post-Exablate Pregnancy Outcomes Registry Study: Exablate Treatment of Symptomatic Uterine Fibroids

NCT05386615
View directory record Official record
Conditions
Uterine Fibroid
Interventions
Body System - Functional
Device
Lead sponsor
InSightec
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
3
States / cities
Los Angeles, California • Stanford, California • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Oct 9, 2026, 3:58 PM EDT
Completed Not applicable Interventional

Implementation of Uterine Fibroid Option Grid Patient Decision Aids Across Five Organizational Settings

NCT03985449
View directory record Official record
Conditions
Uterine Fibroid
Interventions
Uterine Fibroid Option Grid encounter patient decision aid (text only), Uterine Fibroid Option Grid encounter patient decision aid (text + Pictures), Uterine Fibroid Option Grid encounter patient decision aid (online)
Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
748 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Oct 9, 2026, 3:58 PM EDT
Terminated Phase 2 Interventional

Green Tea Extract: a Non-Surgical Alternative for Treatment of Uterine Fibroids

NCT01311869
View directory record Official record
Conditions
Leiomyoma
Interventions
EGCG ( Green Tea extract), Brown rice pills
Dietary Supplement
Lead sponsor
Meharry Medical College
Other
Eligibility
18 Years and older · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 24, 2013 · Synced Oct 9, 2026, 3:58 PM EDT
Completed No phase listed Observational

Official Record of Patients Diagnosed With Lymphangioleiomyomatosis (LAM)

NCT00001869
View directory record Official record
Conditions
Leiomyomatosis
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 9, 2026, 3:58 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Telapristone Acetate (Proellex®) Administered Vaginally for the Treatment of Uterine Fibroids

NCT02323646
View directory record Official record
Conditions
Uterine Fibroids
Interventions
Placebo, Telapristone Acetate
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 47 Years · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
8
States / cities
Fort Lauderdale, Florida • Sandy Springs, Georgia • Metairie, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Oct 9, 2026, 3:58 PM EDT
Completed No phase listed Observational

Fibroid Growth Study

NCT00340288
View directory record Official record
Conditions
Uterine Leiomyomas
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
18 Years to 60 Years · Female only
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 6, 2020 · Synced Oct 9, 2026, 3:58 PM EDT
Terminated Not applicable Interventional Results available

Doppler-Guided Uterine Artery Occlusion (DUAO) Device for Fibroid Related Bleeding

NCT00496080
View directory record Official record
Conditions
Menorrhagia, Uterine Fibroids
Interventions
Doppler-Guided Uterine Artery Occlusion Device (DUAO)
Device
Lead sponsor
Ethicon, Inc.
Industry
Eligibility
25 Years to 50 Years · Female only
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
9
States / cities
Phoenix, Arizona • Fort Lauderdale, Florida • Southfield, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2012 · Synced Oct 9, 2026, 3:58 PM EDT